Expansion Plans - Hims and Hers is expanding its telehealth platform globally, moving from the US and UK to Germany, Spain, France, Ireland, and Canada by the end of 2025 [1] - The company has completed an all-cash acquisition of Live Well, a Canadian digital health provider focused on weight loss care, which positions Hims and Hers in a market where two-thirds of adults are living with obesity [2] Product Rollout - The acquisition sets the stage for a full rollout of weight loss products in the upcoming year, coinciding with the expected availability of the first generic semaglutide, a drug similar to Novo's blockbuster offerings [3] - The introduction of lower-cost generics is anticipated to significantly impact affordability and demand for obesity therapies [4] Market Dynamics - Hims and Hers' CEO highlighted that unbranded GLP-1s represent a unique opportunity to assess the effects of a different price point on public health, potentially pressuring major pharmaceutical companies like Novo and Eli Lilly to reduce their prices [4] - Although no supplier has been secured in Canada for the generic drugs yet, an unbranded version is expected to be approved by June 2026 at approximately half the price of branded alternatives [5]

Group 1 - Pharma, biotech, and healthcare stocks in Asia are experiencing declines following President Trump's announcement of a 100% tariff on branded or patented drugs entering the United States, effective October 1st [1] - An exemption from the tariff will be available for companies that are establishing drug manufacturing plants in the U.S., including those already in the process of building [2] - European companies such as AstraZeneca, RO, and Novartis are planning significant investments in the U.S. over the next four to five years to mitigate potential impacts from tariffs [3] Group 2 - Analysts at JP Morgan suggest that large-cap biopharma companies are likely to avoid the new tariffs due to their increased presence in the U.S. and inventory builds that will limit exposure until mid-next year [4] - A company with 13 manufacturing sites in the U.S. reports having free capacity and is well-prepared for potential tariff impacts, indicating a favorable trade balance with more exports than imports in certain active ingredients [5] - The clarity regarding future operations allows companies to effectively set up their supply chains and operations in response to the evolving trade landscape [6]